DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/shj9lh/gauchers_disease) has announced the addition of the "Gaucher's Disease - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Gaucher's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gaucher's Disease and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Actelion Ltd
- Amicus Therapeutics, Inc.
- Bioorganic Research and Services S.A.
- Biosidus S.A.
- Dong-A Socio Group
- Genzyme Corporation
- greenovation Biotech GmbH
- ISU ABXIS Co.,Ltd.
- JCR Pharmaceuticals Co., Ltd.
- Lixte Biotechnology Holdings, Inc.
- Neuraltus Pharmaceuticals, Inc.
- Okklo Life Sciences BV
- Pharming Group N.V.
- Protalix BioTherapeutics, Inc.
- The International Biotechnology Center (IBC) Generium
- UAB Profarma
- afegostat tartrate + ERT
- imiglucerase biosimilar
- Recombinant Enzyme to Replace Beta Glucosidase 2 for Gaucher's Disease and Male Infertility
- Recombinant Enzyme to Replace Beta-Cerebrosidase for Gaucher's Disease
- Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease
- Small Molecule to Activate Glucocerebrosidase for Parkinson's, Gaucher's and Neurodegenerative Diseases
- Small Molecules to Activate Glucocerebrosidase for Gaucher and Parkinson Disease
- Small Molecules to Inhibit Alpha-glucosidase for Diabetes and Gaucher's Disease
- taliglucerase alfa
For more information visit http://www.researchandmarkets.com/research/shj9lh/gauchers_disease